Non-exhaustive list of disclosed C3 targeting therapeutics
| Drug name | Company | Modality | Highest clinical stage achieved | Target indications |
|---|---|---|---|---|
| Pegcetacoplan (APL-2, POT-4) | Apellis | PEGylated cyclic peptide | Marketed | GA: marketed, PNH: marketed, C3G: phase 3 |
| AMY-101 | Amyndas | Cyclic peptide | Phase 2 | Periodontitis: phase 2, COVID-19: phase 2 ongoing, C3G: phase 2 planned, PNH: phase 2 planned, kidney transplantation: phase 2 planned |
| ARO-C3 | Arrowhead | siRNA | Phase 1 | G3G: phase 1/2, IgAN: phase 1/2, development stopped? |
| ALXN2030 | Alexion/AstraZeneca/Novo Nordisk | siRNA | Phase 1 | Chronic active AMR: phase 1 |
| APL-3007 | Apellis | GalNAc conjugated siRNA | Phase 1 | Healthy volunteers: phase 1 |
| CB2782 | Catalyst Biosciences | PEGylated C3-protease | Preclinical | GA: planned, development stopped? |
| ALN-CC3 | Alnylam | GalNAc conjugated siRNA | Preclinical | Development stopped? |
| SLN-501 | Silence/Mallinckrodt | GalNAc conjugated siRNA | Preclinical | Not disclosed |
| CB-101/501/601/801 | Cascade Biotech | Not disclosed | Preclinical | Not disclosed |
| STP146G | Sirnaomics | GalNAc conjugated siRNA | Preclinical | Not disclosed |
| KNP-301 | Kanaph/Samsung Biologics | Bi-specific C3b and VEGF mAb | Preclinical | Retinal disease |
| KNP-302 | Kanaph | Bi-specific C3b and CD59 mAb | Preclinical | Not disclosed |
GalNAc: N-acetylgalactosamine; aHUS: atypical haemolytic uremic syndrome; AMR: antibody-mediated rejection; C3G: C3 glomerulopathy; COVID-19: coronavirus disease 2019; IgAN: IgA nephropathy; mAb: monoclonal antibody; PNH: paroxysmal nocturnal haemoglobinuria; siRNA: silencing ribonucleic acid; GA: geographic atrophy; VEGF: vascular endothelial growth factor